Cargando…

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa

BACKGROUND: Toxicity of the oral and gastrointestinal mucosa induced by high-dose melphalan is a clinical challenge with no documented prophylactic interventions or predictive tests. The aim of this study was to describe molecular changes in human oral mucosa and to identify biomarkers correlated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcussen, Mette, Bødker, Julie Støve, Christensen, Heidi Søgaard, Johansen, Preben, Nielsen, Søren, Christiansen, Ilse, Bergmann, Olav Jonas, Bøgsted, Martin, Dybkær, Karen, Vyberg, Mogens, Johnsen, Hans Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215401/ https://www.ncbi.nlm.nih.gov/pubmed/28052121 http://dx.doi.org/10.1371/journal.pone.0169286

Ejemplares similares

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma
por: Marcussen, Mette, et al.
Publicado: (2018)

Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma
por: Bøgsted, Martin, et al.
Publicado: (2013)

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition
por: Falgreen, Steffen, et al.
Publicado: (2014)

Reproducible probe-level analysis of the Affymetrix Exon 1.0 ST array with R/Bioconductor
por: Rodrigo-Domingo, Maria, et al.
Publicado: (2014)

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
por: Reinholdt, Linn, et al.
Publicado: (2016)

Long Noncoding RNA Expression during Human B-Cell Development
por: Petri, Andreas, et al.
Publicado: (2015)

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
por: Marques, Sara Correia, et al.
Publicado: (2014)

miR-155 as a Biomarker in B-Cell Malignancies
por: Due, Hanne, et al.
Publicado: (2016)

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow – A proof of concept study
por: Nørgaard, Caroline Holm, et al.
Publicado: (2018)

Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man
por: Bergkvist, Kim Steve, et al.
Publicado: (2014)

A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells
por: Kloster, Maria Bro, et al.
Publicado: (2012)

Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives
por: Vesteghem, Charles, et al.
Publicado: (2019)

Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines
por: Boegsted, Martin, et al.
Publicado: (2011)

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
por: Bilgrau, Anders E., et al.
Publicado: (2016)

Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact
por: Schönherz, Anna A., et al.
Publicado: (2020)

Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission
por: Bødker, Julie Støve, et al.
Publicado: (2017)

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine
por: Falgreen, Steffen, et al.
Publicado: (2016)

High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients
por: Laursen, Maria Bach, et al.
Publicado: (2019)

Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature
por: Boysen, Anders Kindberg, et al.
Publicado: (2011)

Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)
por: Vyberg, Mogens, et al.
Publicado: (2015)

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models
por: Falgreen, Steffen, et al.
Publicado: (2015)

Double versus single high-dose melphalan 200 mg/m(2) and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area
por: Björkstrand, Bo, et al.
Publicado: (2009)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Pilot study protocol of a randomized controlled trial for the potential effects of creatine monohydrate on persistent post-concussive symptoms
por: Bødker, Ronni Lykke, et al.
Publicado: (2023)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Lessons Learned, Challenges Taken, and Actions Made for “Precision” Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program
por: Nielsen, Søren, et al.
Publicado: (2023)

DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review
por: Danstrup, Christian Sander, et al.
Publicado: (2020)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma
por: Issa, Issa Ismail, et al.
Publicado: (2021)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Role of Curcumin in Reducing Toxicities Associated With Mucosal Injury Following Melphalan-Based Conditioning in Autologous Transplant Setting
por: Punatar, Sachin, et al.
Publicado: (2022)

Getting controls under control: the time is now for immunohistochemistry
por: Torlakovic, Emina Emilia, et al.
Publicado: (2015)

p57 in Hydatidiform Moles: Evaluation of Antibodies and Expression in Various Cell Types
por: Lund, Helle, et al.
Publicado: (2020)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_d2d1p96326km18tna7rrl5js1v